Evidence map›Paper›PMID 40359068›Full record

ArticleEmerging infectious diseases2025

Leveraging a Strategic Public-Private Partnership to Launch an Airport-Based Pathogen Monitoring Program to Detect Emerging Health Threats.

Cindy R Friedman, Robert C Morfino, Ezra T Ernst

Abstract read
In one paragraph

Article in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Cindy R Friedman
Robert C Morfino
Ezra T Ernst

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Airport-based pathogen monitoring is a critical tool that can contribute to early detection and characterization of existing and new pathogen threats. A novel public-private partnership between an airport spa group, a biotech company, and the Centers for Disease Control and Prevention was instrumental in establishing a multimodal pathogen genomic surveillance program at US international airports. That public-private partnership addressed critical challenges that neither party could overcome independently, resulting in the development and deployment of a scalable, flexible early warning system for pathogen detection and public health monitoring.

Indexed as

AirportsCommunicable Diseases, EmergingPublic Health SurveillancePublic-Private Sector PartnershipsCenters for Disease Control and Prevention, U.S.HumansUnited Statesairplane wastewater surveillancebiosecurityCOVID-19early detectioninnovationoutbreak identificationpandemic preparednesspublic health monitoringpublic–private partnershipsrespiratory infectionsSARS-CoV-2traveler-based genomic surveillancetravelersvariantsviruseswhole genome sequencing

Identifiers

PMID40359068
PMCPMC12078540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.